Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
New data from the DESTINY-Breast03 trial presented at SABCS 2021 show that AstraZeneca and Daiichi Sankyo’s ENHERTU demonstrated superior progression-free survival (PFS) and objective response rate (ORR) in HER2-positive breast cancer patients compared to T-DM1. In a subgroup with stable brain metastases, ENHERTU achieved a median PFS of 15 months versus 3 months for T-DM1. Overall, the confirmed ORR was 67.4% for ENHERTU against 20.5% for T-DM1. ENHERTU is gaining recognition for its potential to improve treatment options for patients with previously treated HER2-positive metastatic breast cancer.
The DESTINY-Breast03 phase 3 trial results presented at SABCS 2021 show that ENHERTU (trastuzumab deruxtecan) significantly outperforms T-DM1 in treating HER2 positive metastatic breast cancer. ENHERTU demonstrated higher progression-free survival (PFS) and objective response rate (ORR), particularly in patients with stable brain metastases. Notably, PFS for these patients was 15 months for ENHERTU compared to just 3 months for T-DM1. The safety profile remains consistent, with a low incidence of severe adverse events. These findings suggest ENHERTU's potential as a new standard of care.
AstraZeneca's EVUSHELD, a long-acting antibody combination, has received emergency use authorization (EUA) from the FDA for COVID-19 pre-exposure prophylaxis. Designed for patients aged 12 and older with moderate to severe immune compromise, it provides long-term protection. Data from the PROVENT Phase III trial indicated a significant reduction in symptomatic COVID-19 cases, showing 83% efficacy at six months post-administration. AstraZeneca plans to supply 700,000 doses to the US government, aiming for global filings for further authorization.
Updated results from the TNBC cohort of the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan by Daiichi Sankyo and AstraZeneca showed a 34% objective response rate (ORR) in 44 patients with metastatic triple negative breast cancer (TNBC). In a subgroup of 27 untreated patients, the ORR was 52%. The disease control rate (DCR) was 77% overall, with no new safety signals reported. AstraZeneca plans to initiate a registrational phase 3 study based on these encouraging outcomes, addressing a critical need in TNBC treatment.
AstraZeneca highlights its commitment to redefining breast cancer care at the 2021 San Antonio Breast Cancer Symposium, showcasing data from 14 medicines and potential new treatments across 33 abstracts. Key data from the DESTINY-Breast03 trial confirms the efficacy of ENHERTU for HER2-positive metastatic breast cancer. Notable presentations include promising results from BEGONIA and TROPION-PanTumor01 trials, focusing on personalized medicine approaches. The OlympiA trial illustrates the quality of life improvements associated with LYNPARZA for early breast cancer patients. The company emphasizes a diverse portfolio aimed at improving outcomes for breast cancer patients.
Daiichi Sankyo announced the initiation of the DESTINY-Breast11 phase 3 trial, investigating ENHERTU (trastuzumab deruxtecan) as a neoadjuvant therapy for high-risk HER2 positive early-stage breast cancer. This global trial aims to evaluate ENHERTU's efficacy against the current standard of care, assessing its potential to improve patient outcomes while reducing treatment toxicity. Approximately 624 patients will be enrolled across various regions, with a primary focus on achieving a pathologic complete response (pCR) before surgery.
AstraZeneca's supplemental New Drug Application for LYNPARZA® (olaparib) has been accepted for Priority Review in the US, targeting BRCA-mutated HER2-negative high-risk early breast cancer. The FDA's Priority Review is reserved for drugs that offer significant clinical advantages, with a decision expected in Q1 2022. LYNPARZA demonstrated a 42% reduction in cancer recurrence risk based on the OlympiA Phase III trial. This marks a significant milestone in adjuvant therapy, as breast cancer remains the most diagnosed cancer globally, with 2.3 million cases in 2020.
Tempus announced a multi-year strategic collaboration with AstraZeneca (AZN) to advance oncology drug discovery and development. The partnership aims to leverage Tempus' AI and multimodal data repository to enhance AstraZeneca's research and development efforts. The collaboration seeks to identify novel drug targets and will utilize AI-enabled solutions for better therapeutic outcomes. Both companies expressed optimism about transforming cancer treatment through advanced data analysis.
Daiichi Sankyo has initiated the global TROPION-Breast01 phase 3 trial, assessing the safety and efficacy of datopotamab deruxtecan (Dato-DXd) for treating inoperable or metastatic HR positive, HER2 negative breast cancer. This ADC aims to address significant unmet needs among patients previously treated with chemotherapy, as current therapies show diminished efficacy. Approximately 700 patients will be enrolled across multiple regions globally. The dual primary endpoints focus on progression-free survival and overall survival, marking a pivotal step in oncology development.
AZD7442, AstraZeneca's COVID-19 treatment, demonstrated significant effectiveness in recent studies. The PROVENT trial showed an 83% reduction in symptomatic COVID-19 cases among participants treated with a single 300mg dose, with no severe cases or deaths reported. Meanwhile, the TACKLE trial revealed an 88% decrease in severe COVID-19 or death for patients treated within three days of symptoms. AstraZeneca plans to submit findings for regulatory approval and has already secured agreements for 700,000 doses from the U.S. Government.